Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries

被引:137
作者
Schwartz, M [1 ]
Kipnis, J [1 ]
机构
[1] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel
关键词
D O I
10.1016/S1471-4914(01)01993-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neuronal degeneration after traumatic injury to the central nervous system (CNS) can be reduced by active immunization or passive transfer of T cells against CNS-associated myelin antigens, We propose that a protective autoimmunity is evoked by CNS insult when non-immunological local protective mechanisms cannot adequately buffer the injury-induced toxicity. The ability of a particular strain to develop a protective autoimmune response appears to be inversely related to its susceptibility to autoimmune disease. We also propose that vaccination with specific CNS-derived 'safe' (non-pathogenic) peptides after traumatic CNS insult, and possibly at any stage of chronic neurodegenerative disease, can be used to boost the protective autoimmunity acid thereby to reduce further injury-induced damage. Such therapeutic vaccination ensures that the augmented beneficial autoimmunity will be free of accompanying disease.
引用
收藏
页码:252 / 258
页数:7
相关论文
共 54 条
[1]   Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking [J].
Aharoni, R ;
Teitelbaum, D ;
Arnon, R ;
Sela, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (02) :634-639
[2]   Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1 [J].
Aharoni, R ;
Teitelbaum, D ;
Sela, M ;
Arnon, R .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 91 (1-2) :135-146
[3]  
Bernard C C, 1991, Acta Neurol (Napoli), V13, P171
[4]   Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand [J].
Bielekova, B ;
Goodwin, B ;
Richert, N ;
Cortese, I ;
Kondo, T ;
Afshar, G ;
Gran, B ;
Eaton, J ;
Antel, J ;
Frank, JA ;
McFarland, HF ;
Martin, R .
NATURE MEDICINE, 2000, 6 (10) :1167-1175
[5]  
Butovsky Oleg, 2001, FASEB Journal, V15, P1065
[6]   THE COGNITIVE PRINCIPLE CHALLENGES CLONAL SELECTION [J].
COHEN, IR .
IMMUNOLOGY TODAY, 1992, 13 (11) :441-444
[7]   Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen [J].
Diaz-Villoslada, P ;
Shih, A ;
Shao, L ;
Genain, CP ;
Hauser, SL .
JOURNAL OF NEUROIMMUNOLOGY, 1999, 99 (01) :36-43
[8]   Vβ8+ T cells protect from demyelinating disease in a viral model of multiple sclerosis [J].
Drescher, KM ;
Johnston, SL ;
Hogancamp, W ;
Nabozny, GH ;
David, CS ;
Rimm, IJ ;
Wettstein, PJ ;
Rodriguez, M .
INTERNATIONAL IMMUNOLOGY, 2000, 12 (03) :271-280
[9]   EFFECT OF ANTI-INTERFERON-GAMMA MONOCLONAL-ANTIBODY TREATMENT ON THE DEVELOPMENT OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN RESISTANT MOUSE STRAINS [J].
DUONG, TT ;
FINKELMAN, FD ;
SINGH, B ;
STREJAN, GH .
JOURNAL OF NEUROIMMUNOLOGY, 1994, 53 (01) :101-107
[10]  
FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175